Jubilant Sees No Material Impact From Coronavirus-Led Plant Closure, For Now
Evaluates Manufacture Of Recently Incentivized APIs
Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.
